Article

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of mocravimod in Healthy Volunteers

2026-05-26

Abstract excerpt

<h4>Background</h4> Mocravimod is an oral sphingosine-1-phosphate (S1P) receptor modulator. This Phase 1 multiple-ascending-dose study evaluated its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers. <h4>Methods</h4> In this double-blind, randomized, placebo-controlled, parallel-group trial, 60 healthy male volunteers were enrolled in five cohorts. Mocravimod was admini...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 82a061b8-4fcc-577b-a7fa-21aea1e61246
DOI: 10.64898/2026.05.22.26353846

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of mocravimod in Healthy VolunteersDOI 10.64898/2026.05.22.26353846Read

Safety and pharmacokinetic profile of pretomanid (PA-824) in healthy Chinese participants: Results of a phase I single dose escalation studySemantic proximity Read

The Impact of Sphinogosine-1-Phosphate Receptor Modulators on COVID-19 and SARS-CoV-2 VaccinationSemantic proximity Read

The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers.Semantic proximity Read

Pseudoirreversible inhibition elicits persistent efficacy of a sphigosine-1-phosphate receptor-1 antagonistSemantic proximity Read

A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers.Semantic proximity Read

S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate.Semantic proximity Read

Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype.Semantic proximity Read

Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.Semantic proximity Read

Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single center open-label clinical phase I trial (NEON trial)Semantic proximity Read

2003 ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND TOLERABILITY OF AZD7295, A NOVEL NS5A INHIBITOR, IN A PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY IN HCV GENOTYPE 1 AND 3 PATIENTSSemantic proximity Read

First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitorSemantic proximity Read

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod.Semantic proximity Read